Market Research Logo

Competitor Landscape: Graft Versus Host Disease (GVHD)

Competitor Landscape: Graft Versus Host Disease (GVHD)

Summary

Competitor Landscape: Graft Versus Host Disease (GVHD), briefings contain evaluations of ongoing development activities within the GVHD market, together with analysis of current & potential future product positioning.

Key Highlights from the report -

  • Anticipated approval of ATIR101 is delayed both in the EU and US - with the postponed primary completion date in the ongoing Phase III trial delaying the expected US approval by 9 months
  • If approved, Ruxolitinib for use in combination with corticosteroids for the treatment of steroid-refractory aGVHD would make it the second drug to receive US approval for the treatment of GVHD after Janssen/AbbVie’s IBR
  • Incyte has not only delayed the initiation of Itacitinib's GRAVITAS-309 trial, but significantly extended its duration (from ~2.5 years to ~4.5 years)
The report comprises four key sections.

Executive Summary: Contains analysis of key market events that have occurred during the period 10 August 2018 - 10 November 2018 which have impacted the GVHD landscape

Landscape Updates: Section contains the following analysis -
  • ‘Order of Entry’ analysis, containing detailed timeline forecasts for each drug in Phase II development or higher, and timeline forecasts for each approved product’s lifecycle management initiatives.
  • ‘Direction of Travel’ analysis for currently approved therapies, together with an assessment of initial market entry strategies for key pipeline candidates.
Approved & Pipeline Product Landscape: Section contains the following analysis -
  • An overview of pipeline & approved products, containing snapshots of current development status
  • Expected drug-specific events & milestones until YE 2020
Appendix: Data slides containing the following information -
  • Current Early Stage GVHD Pipeline & candidate ‘Watch List’.
  • Timeline Assumptions, including standard assumptions & drug-specific assumptions.
Scope
  • The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy
  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.


Introduction to Sociable Pharma’s GVHD ‘Competitor Landscape’
Executive Summary
Overall GVHD Landscape
Key Events & Landscape Updates
Landscape Updates
Order of Entry
‘Direction of Travel’ & Market Entry Strategies
Pipeline & Approved Product Landscape
Overview: Pipeline & Approved Biologics & Small Molecules
Events & Milestones: 2017-20
Appendix

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report